Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332184 | 1.00 | CES2 (0.50) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL30944840 | 0.93 | DAO (0.44) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL8298426 | 0.82 | TSHR (0.55) | CES2CES1KEAP1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL4126481 | 0.81 | TSHR (0.54) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL13116466 | 0.79 | TSHR (0.49) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL11245259 | 0.79 | CYP2C19 (0.53) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL10761013 | 0.76 | CES2 (0.55) | CES2CES1KEAP1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL10810413 | 0.74 | RAB9A (0.53) | CES2CES1KEAP1KMT2AMAPT | |
| SCHEMBL13116484 | 0.73 | ALDH1A1 (0.49) | CES2CES1KEAP1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL3418543 | 0.73 | DAO (0.53) | CES2CES1KEAP1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374480-A2 | Mutli-drug ligand conjugates | Endocyte, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20080124765-A1 | EXPRESSION OF FUNCTIONAL ANTIBODY FRAGMENTS | GENENTECH, INC. (US) | 2008-05-29 | — | — | US | claimed |
| JP-3951062-B2 | — | — | 2007-08-01 | — | — | JP | claimed |
| US-5648237-A | Expression of functional antibody fragments | GENENTECH, INC. (US) | 1997-07-15 | — | — | US | claimed |
| EP-0604580-A1 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES | GENENTECH, INC. (US) | 1994-07-06 | — | — | EP | claimed |
| WO-1993006217-A1 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES | GENENTECH, INC. (US) | 1993-04-01 | — | — | WO | claimed |
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4736892-A2 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | Cerus Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3852817-B1 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | CERUS CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | CERUS CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | AUCKLAND UNISERVICES LTD (NZ) | 2025-09-11 | — | — | US | disclosed |
| US-20250270610-A1 | Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-08-28 | — | — | US | disclosed |
| WO-2025007126-A9 | COMPOSITIONS COMPRISING NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWN-REGULATED 9 (NEDD9)-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-0604580-A1 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES | GENENTECH, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993006217-A1 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES | GENENTECH, INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0487648-A4 | ODOR-MASKED AND STABILIZED COMPOSITIONS FOR TREATING KERATINOUS TISSUE, SKIN CONDITIONS, AND PROMOTING WOUND HEALING | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0487648-A1 | ODOR-MASKED AND STABILIZED COMPOSITIONS FOR TREATING KERATINOUS TISSUE, SKIN CONDITIONS, AND PROMOTING WOUND HEALING | JOHN MORRIS CO., INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| US-5059421-A | Stable protein-liposome conjugate exhibiting an absence of aggregation | THE LIPOSOME COMPANY, INC. (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1991002538-A1 | ODOR-MASKED AND STABILIZED COMPOSITIONS FOR TREATING KERATINOUS TISSUE, SKIN CONDITIONS, AND PROMOTING WOUND HEALING | JOHN MORRIS CO., INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991000289-A2 | TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING | THE LIPOSOME COMPANY, INC. (US) | 1991-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | PRF1, CFD, F5 | CES2 3283/4885CES1 2462/4885KEAP1 604/4885 |
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | PHOSPHO1, PCTP, PTMS | CES2 4560/4885CES1 2778/4885KEAP1 3066/4885 |
| US-20250270610-A1 | Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme | QPCT, GLUL, QPCTL | CES2 2879/4885CES1 1561/4885KEAP1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.